NCT05535595View on ClinicalTrials.gov

Precision Treatment With Angiotensin Converting Enzyme Inhibitor

PHASE4CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

August 2, 2021

Study Completion Date

August 2, 2021

Conditions
Hypertension
Interventions
DRUG

genotyping and selection of renin-angiotensin system blocker

"One of perindopril or candesartan was chosen based on genotyping results on two NELL1 variants.~* perindopril 4 mg/d after genotyping~* candesartan 8 mg/d after genotyping"

DRUG

Perindopril

perindopril 4 mg/d without genotyping

Trial Locations (1)

Unknown

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT05535595 - Precision Treatment With Angiotensin Converting Enzyme Inhibitor | Biotech Hunter | Biotech Hunter